Seelos therapeutics doses the first amyotrophic lateral sclerosis (als) patient with sls-005 in an expanded access program

- the expanded access program is funded by a grant from the national institute of neurological disorders and stroke (ninds) under the accelerating access to critical therapies for als (act for als) for als patients who do not qualify for existing clinical trials new york , april 4, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has dosed the first patient in an expanded access program (eap) for patients with als who do not qualify for existing clinical trials and that the eap will be fully funded by a grant from the ninds under the act for als. under this eap, seelos plans to initially enroll 70 patients in a 24-week, open-label study to evaluate sls-005 in persons with als in parallel to its ongoing, fully enrolled, randomized double-blind placebo-controlled phase ii/iii study on the healey als platform.
SEEL Ratings Summary
SEEL Quant Ranking